Company
Company

Technology powers us. Drug development defines us.

Technology powers us. Drug development defines us.

Novorex is a drug development company integrating AI, FBDD, and biophysical validation to identify real binders and advance high-unmet-need CNS and inflammation pipelines.

Novorex is a drug development company integrating AI, FBDD, and biophysical validation to identify real binders and advance high-unmet-need CNS and inflammation pipelines.

04 / Company History
Execution milestones since 2020

Novorex has built a validated execution track record through funding milestones, R&D center expansion, strategic partnerships, and national project selections.

04 / 05
2026

Jan.MOU Signed with BTT Group and Certara

Feb.Awarded Top Excellence in Global Corporate Collaboration Program Evaluation

Apr.Selected for SK Biopharmaceuticals–Seoul Biohub Open Innovation Program

2025

Apr.Selected for Global Corporate Collaboration Program

Apr.Selected for National New Drug Development Program (KDDF)

May.Platform Service Contract Executed with Nexel

2024

May.Selected for Technology Protection System Implementation Support Program

Apr.MOU Signed with Almac Group

Oct.Selected for National New Drug Development Program (KDDF)

Oct.Selected for Advanced Bio Promotion R&D Support Program

Dec.Designated as a KBSI Family Company

2023

Sep.Completed Series A Bridge Financing (KRW 11.5 Billion)

Nov.Received Minister of Health and Welfare Award

2022

Nov.MOU Signed with Dong-A ST

Mar.Central Research & Development Center Established

2021

Oct.Jeongeup Research Laboratory Established

Oct.Pangyo Research Laboratory Established

Sep.Completed Series A Financing (KRW 10.5 Billion)

2020

Feb.Company Established

Mar.Selected for TIPS Program